Several biotech startups have recently secured substantial funding rounds to advance their drug development programs. GlycoEra, a protein degrader company focused on extracellular degraders for autoimmune diseases, raised $130 million in a Series B financing to support its clinical entry. ProteinQure closed an $11 million Series A round and plans to begin clinical trials later this year with its first drug candidate, a peptide-drug conjugate targeting triple-negative breast cancer. Lexeo Therapeutics announced an $80 million equity financing led by Frazier Life Sciences and Janus Henderson Investors to further develop genetic medicines for cardiovascular diseases. Additionally, David Protein raised $75 million in a Series A round from Greenoaks and Valor Equity, following a $10 million launch round led by Peter Rahal. David Protein has also acquired its supplier within its first year of operation.